Dipexium Pharmaceuticals' Pexiganan Demonstrates Microbiological Activity Against Pathogens Resistant to other Topical Antibiotics

Abstract accepted for poster presentation at ICAAC/ICC 2015

Jul 28, 2015, 08:00 ET from Dipexium Pharmaceuticals, Inc.

NEW YORK, July 28, 2015 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), today announced that new Locilex® microbiology data will be presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific meeting in San Diego, California, September 17-21, 2015.

Dipexium and its research collaborators, will present data on pexiganan, the active pharmaceutical ingredient in Locilex®, that highlight pexiganan's activity against a broad spectrum of bacteria resistant to seven marketed or investigational topical antimicrobials.

Poster Title: In Vitro Activity of Pexiganan Tested Against Pathogens with Elevated MICs to Topical Antimicrobials

Poster Board Number: F-730

Date and Time: Saturday, September 19, 11 a.m. - 1 p.m. PT

Session / Location: Poster Session 095: Antimicrobial Peptides / Exhibit Hall F

A copy of the ICAAC/ICC poster presentation will be uploaded to Dipexium's website at 11 a.m. PT on the day of the presentation.

About ICAAC/ICC (www.icacc.org)

ICAAC/ICC, the premier conference on antimicrobial agents and infectious diseases, showcases the latest-breaking science and lectures from top researchers from around the world. With over 60% of its attendees living outside of the United States, ICAAC provides a rare opportunity to bring together the field's foremost leaders to discuss the state of infection control and prevention on a global scale. Through oral and poster presentations, 10,000 physicians, clinical microbiologists, researchers, and pharmacists will come together to share their research, discover the latest breakthroughs, and work towards fostering global solutions to the problems of infectious diseases and antimicrobial agents.

About Dipexium Pharmaceuticals, Inc.

Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of Mild DFI. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA).  For more information, visit www.dipexiumpharmaceuticals.com.

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of Dipexium Pharmaceuticals, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy. Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submission for Locilex®) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Company Contacts:

David P. Luci President & Chief Executive Officer Dipexium Pharmaceuticals, Inc. 212-269-2834 davidluci@dipexium.com

David Garrett Vice President, Finance & Corporate Development Dipexium Pharmaceuticals, Inc. 212-269-2834 davidgarrett@dipexium.com

© 2015 Dipexium Pharmaceuticals, Inc.  All rights reserved.

 

SOURCE Dipexium Pharmaceuticals, Inc.



RELATED LINKS

http://www.dipexiumpharmaceuticals.com